Protective Properties of Silymarin Against the Toxic Effects of Valproic Acid in the Heart
7th International Conference and Exhibition onPharmacology and Ethnopharmacology, Amsterdam, Hollanda, 27 - 28 Mart 2019, ss.1, (Özet Bildiri)
- Yayın Türü: Bildiri / Özet Bildiri
- Doi Numarası: 10.4066/2249-622x-c1-017
- Basıldığı Şehir: Amsterdam
- Basıldığı Ülke: Hollanda
- Sayfa Sayıları: ss.1
- Süleyman Demirel Üniversitesi Adresli: Evet
Özet
The aim of this study was to investigate the protective effect of silymarin against the effects of
valproic acid (VPA) in the heart of rats, which is used as a common antiepileptic in the treatment of
epilepsy. VPA is a substance consisting of an eight-carbon fatty acid called dipropylacetate for the
treatment of epilepsy. It is used in both parsiel and generalized epilepsy because it is effective in
many seizures such as myoclonic, atonic, absorptive, tonic and tonic-clonic. Moreover, exposure to
VPA has been shown to induce cardiac malformations in rats. It, due to its similarity to GABA, an
inhibitor amino acid, inhibits GABA transaminase and reduces GABA withdraw from the
presynaptic junction by increasing the amount of GABA in the synaptic junction. Silymarin is known
to have a positive inotropic effect on the perfused adult rat heart. For 14 days, rats were divided
into 3 groups as placebo control, VPA, VPA+silymarin. The group were given 500 mg/kg/day from
VPA or/and 100 mg/kg/day from silymarin for 14 days, except placebo control group. At 15 day, all
animals were sacrificed after blood samples collected to assay of biochemical parameters such as
glucose, albumin, amylase, bilirubin, calcium, total cholesterol, creatinine and triglyceride. All
statistical analyzes were calculated by S.E.M ± in the graphpad prism program and p <0.05 was
found to be statistically significant. Total chlosterol, albumin, amylase and creatinine count
significantly increased in the VPA+silymarin group but in the VPA group it’s count statistically
decreased compared to placebo group.